share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中進醫療 | 6-K:外國發行人報告
美股SEC公告 ·  03/29 16:15

Moomoo AI 已提取核心訊息

Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.
Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.
Jin Medical International Ltd.已收到納斯達克聽證小組的贊成決定,批准了該公司繼續在納斯達克股票市場上市的請求。該決定是在該公司此前被告知由於公衆持有人少於所需的300名而未遵守納斯達克上市規則5550(a)(3)之後做出的。儘管恢復了對該規定的遵守,但金醫療國際仍因未提交截至2023年9月30日的財政年度的20-F表年度報告而面臨缺陷。該小組允許該公司繼續上市,條件是該公司必須在2024年5月20日之前提交逾期的年度報告。該公司已確認正在努力在規定的延期內準備和提交報告。
Jin Medical International Ltd.已收到納斯達克聽證小組的贊成決定,批准了該公司繼續在納斯達克股票市場上市的請求。該決定是在該公司此前被告知由於公衆持有人少於所需的300名而未遵守納斯達克上市規則5550(a)(3)之後做出的。儘管恢復了對該規定的遵守,但金醫療國際仍因未提交截至2023年9月30日的財政年度的20-F表年度報告而面臨缺陷。該小組允許該公司繼續上市,條件是該公司必須在2024年5月20日之前提交逾期的年度報告。該公司已確認正在努力在規定的延期內準備和提交報告。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息